Which years have brought AbbVie the highest US and international revenues, respectively, for adalimumab (Humira)?
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.